EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France
Abstract
Authors
V. Leblond C. Souihi J. Ramier B. Manzoor S. Lepretre